Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

26 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Nisoldipine Articles

Skyepharma further reduces loss in first half

8 September 2008

Sciele Pharma reaffirms 2007 guidance

21 January 2008

Stock Commentary - Europe - week to Jan 7, 2008

14 January 2008

FDA clears new Sular formulations

7 January 2008

FDA accepts Sular sNDA

17 September 2007

Stock Commentary - Europe - week to May 14, 2007

21 May 2007

New Sular formulation bioequivalent in trials

21 May 2007

First Horizon sees growing partnership with Bayer

16 January 2006

AstraZeneca and Bayer stop co-marketing Baymycard in Japan

1 April 2002

First Horizon buys US Sular rights from AstraZeneca

25 February 2002

-Forest Laboratories acquires exclusive UK and Ireland marketing rights to

23 February 1999

Calcium Channel Blocker Link To Suicide

11 March 1998

Zeneca Sees Strong Growth Against The Odds

8 August 1997

Zeneca Breaks Records In 1996 As New Products Are Launched

17 March 1997

Benefits Of Bayer's Nisoldipine Shown By DEFIANT II Study

20 January 1997

Bayer's Syscor Launched In UK

25 November 1996

Strong Fundamentals On Show At Zeneca

19 August 1996

Zeneca / Bayer: Sular agreement

22 January 1996

US FDA Approving Fewer NMEs, But Faster, In 1995

11 September 1995

JAMA Study Ups Debate Over Calcium Blockers

4 September 1995

Calcium Blockers In HF: V-HeFT III & DEFIANT II

4 September 1995

Bayer/Zeneca Deal On US Marketing Of Sular

14 August 1995

Bayer hold back Nisocor

22 May 1995

Miles Considers Licensing

13 February 1995

Showing 1-24 of 24 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS